Susquehanna International Group, LLP Applied Genetic Technologies Corp Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$1.87 - $2.91 $181,764 - $282,852	-97,200 Reduced 66.58%	48,800 $93,000
Q3 2021 Nov 15, 2021	BUY	$3.01 - $4.12 $157,724 - $215,888	52,400 Added 55.98%	146,000 $439,000
Q2 2021 Aug 11, 2021	SELL	$3.62 - $5.23 $1.24 Million - $1.8 Million	-343,500 Reduced 78.59%	93,600 $366,000
Q1 2021 May 17, 2021	BUY	$3.94 - $8.19 $1.01 Million - $2.11 Million	257,400 Added 143.24%	437,100 $2.22 Million
Q4 2020 Feb 16, 2021	SELL	$3.99 - $5.7 $126,483 - $180,690	-31,700 Reduced 15.0%	179,700 $735,000
Q3 2020 Nov 16, 2020	BUY	$4.38 - $6.43 $328,062 - $481,607	74,900 Added 54.87%	211,400 $1.03 Million
Q2 2020 Aug 14, 2020	BUY	$3.0 - $6.9 $153,900 - $353,970	51,300 Added 60.21%	136,500 $756,000
Q1 2020 May 15, 2020	BUY	$2.36 - $9.86 $123,664 - $516,663	52,400 Added 159.76%	85,200 $279,000
Q4 2019 Feb 14, 2020	SELL	$2.69 - $4.92 $67,519 - $123,492	-25,100 Reduced 43.35%	32,800 $148,000
Q3 2019 Nov 14, 2019	SELL	$2.59 - $4.16 $359,233 - $576,992	-138,700 Reduced 70.55%	57,900 $241,000
Q2 2019 Aug 14, 2019	BUY	$3.6 - $4.78 $169,560 - $225,138	47,100 Added 31.51%	196,600 $745,000
Q1 2019 May 15, 2019	BUY	$2.62 - $4.44 $364,704 - $618,048	139,200 Added 1351.46%	149,500 $626,000
Q3 2018 Nov 14, 2018	SELL	$3.85 - $7.35 $37,730 - $72,030	-9,800 Reduced 48.76%	10,300 $75,000
Q2 2018 Aug 14, 2018	SELL	$3.7 - $5.65 $7,400 - $11,300	-2,000 Reduced 9.05%	20,100 $74,000
Q1 2018 May 15, 2018	SELL	$3.65 - $5.2 $91,980 - $131,040	-25,200 Reduced 53.28%	22,100 $85,000
Q3 2017 Nov 14, 2017	BUY	$3.55 - $5.25 $167,915 - $248,325	47,300	47,300 $187,000

About APPLIED GENETIC TECHNOLOGIES CORP

Ticker AGTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,632,200
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...

More about AGTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account